Skip to main content

Table 1 Baseline patient characters

From: Impact of type 2 diabetes mellitus on mid-term mortality for hypertrophic cardiomyopathy patients who underwent septal myectomy

VariableNo diabetes (n = 134)Diabetes (n = 67)p value
Age, years48.8 ± 13.550.1 ± 13.80.53
Male, n78 (58.2%)41 (61.2%)0.69
Body mass index, kg/m225.9 ± 3.925.6 ± 3.70.69
Family history of HCM or SCD, n18 (13.4%)15 (22.4%)0.11
Heart rate, beats/min72.2 ± 9.372.7 ± 8.50.71
BNP, pg/mL1379.9 (636.3–2342.4)1605.5 (573.7–2726.3)0.71
Creatinine, umol/L77.3 ± 13.476.8 ± 14.80.83
Glomerular filtration rate, ml/min 99.8 ± 20.293.7 ± 18.50.04
Hs-CRP, mg/L0.97 (0.40–1.80)1.30 (0.56–2.28)0.04
LDL, mmol/L2.6 ± 0.92.5 ± 0.60.31
HDL, mmol/L1.2 ± 0.51.16 ± 0.30.63
Comorbidities
 Hypertension, n54 (40.3%)28 (41.8%)0.84
 Hyperlipemia, n28 (20.9%)15 (22.4%)0.81
Clinical presentation
 Chest pain, n35 (26.1%)20 (29.9%)0.58
 Palpitation, n11 (8.2%)8 (11.9%)0.39
 Syncope, n14 (10.4%)8 (11.9%)0.75
 Atrial fibrillation, n16 (11.9%)19 (28.4%)0.004
Echocardiographic indices
 LVEDD, mm41.8 ± 5.741.5 ± 4.50.70
 IVST, mm20.3 ± 5.620.0 ± 5.80.74
 Posterior wall, mm11.9 ± 2.412.2 ± 2.90.56
 LVEF,  %71.4 ± 5.671.3 ± 5.40.94
 IVST ≥ 30 mm, n11 (8.2%)4 (6.0%)0.57
 Moderate or severe MR24 (17.9%)7 (10.4%)0.17
Medical therapy
 Beta-blockers, n99 (73.9%)50 (74.6%)0.91
 Calcium-channel blockers, n7 (5.2%)7 (10.4%)0.17
 ACEI/ARB, n17 (12.7%)8 (11.9%)0.88
 Statins, n14 (10.4%)11 (16.4%)0.23
 Insulin, n19 (28.4%)
 Metformin, n39 (58.2%)
 Acarbose, n12 (17.9%)
  1. Values are presented as percentage, mean ± SD, or median (interquartile range) when appropriate
  2. IVST interventricular septal thickness, HCM hypertrophic myocardiopathy; SCD sudden cardiac death, NYHA New York Heart Association, BNP brain natriuretic peptide, LVEF left ventricular ejection fraction, LDL low density lipoprotein, HDL high density lipoprotein, LVEDD left ventricular end diastole diameter, LVOT left ventricular outflow tract, MR mitral regurgitation, ACEI/ARB angiotensin-converting enzyme inhibitor or angiotensin receptor blocker